Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discoveries & therapeutics"
DOI: 10.5582/ddt.2022.01085
Abstract: Adult T-cell leukemia/lymphoma (ATL) is a mature T-cell lymphoma with a poor prognosis. Accumulating trimethylation of histone H3 lysine 27 (H3K27me3) caused by upregulated function of either enhancer of zeste homologue 2 (EZH2) or its… read more here.
Keywords: cell; leukemia lymphoma; adult cell; ezh1 ... See more keywords